Researchers analyzed long-term survival of women diagnosed with low-risk cervical cancer, from 2010 through 2017, who ...

The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company ...

U.S. lawmakers on Thursday asked Pfizer Inc for information on alleged comments by a former executive suggesting its research ...

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...

British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine ...

Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab ...

A kidnapped child, a husband with a double life, a treacherous murder plot unraveled when the police arrive at the perfect ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

British pharmaceutical company GSK(GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 ...